Trials / Unknown
UnknownNCT04612894
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab and Apatinib | All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment |
| PROCEDURE | surgery | Perform surgery if operable after neoadjuvant therapy |
| PROCEDURE | core needle biopsy | Perform core needle biopsy if inoperable after neoadjuvant therapy |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2022-12-01
- Completion
- 2023-12-31
- First posted
- 2020-11-03
- Last updated
- 2020-11-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04612894. Inclusion in this directory is not an endorsement.